Compare ING Groep NV (ING) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Mesoblast Limited — how do they compare? ING Groep NV trades at $35.34 (market cap $101.24B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: ING Groep NV is far larger — about 46.9× Mesoblast Limited's market cap, and ING Groep NV pays a 3.74% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ING | MESO | |
|---|---|---|
Market Cap | $101.24B | $2.16B |
Sector | Financials | Technology |
52-Week High | $35.92 | $20.96 |
52-Week Low | $23.66 | $12.88 |
Dividend Yield | 3.74% | — |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $35.68, down slightly by 0.08% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79 versus $0.75 expected, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 10 buy ratings and no sell ratings out of 16 analysts.
The outlook for ING is favorable, supported by earnings momentum and strategic initiatives, though risks include negative cash flow trends and potential market volatility. The stock presents a value opportunity with a P/E of 13.37 and a net income margin of 28.34%, but investors should weigh the persistent cash flow deficits against growth prospects.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
